Home/Pipeline/KT-413

KT-413

B-cell Malignancies

Phase 1Active

Key Facts

Indication

B-cell Malignancies

Phase

Phase 1

Status

Active

Company

Kymera Therapeutics

About Kymera Therapeutics

Kymera Therapeutics is advancing a robust pipeline of PROTAC degraders targeting transcription factors, scaffolding proteins, and other previously undruggable proteins across oncology, immunology, and other therapeutic areas. The company has built a proprietary platform combining computational chemistry, structural biology, and proteomics to design selective protein degraders. With multiple programs in clinical development and strategic partnerships with leading pharmaceutical companies, Kymera is positioned as a leader in the emerging protein degradation field.

View full company profile

Therapeutic Areas

Oncology Immunology Rare Diseases

Other B-cell Malignancies Drugs

Drug	Company	Phase	Status
Pirtobrutinib	Eli Lilly	Phase 3	Active
Mezagitamab	Kyowa Kirin	Phase 1/2	Active
Velexbru (tirabrutinib)	Ono Pharmaceutical	Phase 3	Active
TG-1701	TG Therapeutics	Phase 1	Early-stage (based on general knowledge)
TG-1801	TG Therapeutics	Phase 1	Early-stage (based on general knowledge)
HMPL-760	HUTCHMED	Phase 1	Active
REC-3565	Recursion Pharmaceuticals	Phase 1	Active
UCART20x22	Cellectis	Phase 1/2	Active (in collaboration with Servier)
FT819	Fate Therapeutics	Phase 1	Active
Prulacabtagene leucel (prula-cel, ADI-001)	Adicet Bio	Phase 1	Previously Studied